GLK-221 Ophthalmic Solution + Placebo Ophthalmic Solution
Phase 2Recruiting 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Keratoconus
Conditions
Keratoconus
Trial Timeline
Dec 23, 2025 → Apr 1, 2027
NCT ID
NCT07400952About GLK-221 Ophthalmic Solution + Placebo Ophthalmic Solution
GLK-221 Ophthalmic Solution + Placebo Ophthalmic Solution is a phase 2 stage product being developed by Glaukos for Keratoconus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07400952. Target conditions include Keratoconus.
What happened to similar drugs?
2 of 7 similar drugs in Keratoconus were approved
Approved (2) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07400952 | Phase 2 | Recruiting |
Competing Products
7 competing products in Keratoconus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| riboflavin solution + placebo solution | Glaukos | Phase 3 | 37 |
| riboflavin ophthalmic solution | Glaukos | Phase 3 | 37 |
| riboflavin solution + placebo solution | Glaukos | Phase 3 | 29 |
| Riboflavin 5'-Phosphate | Glaukos | Approved | 40 |
| riboflavin solution + placebo solution | Glaukos | Phase 3 | 37 |
| Test Article A + Test Article B + Placebo | Glaukos | Phase 3 | 37 |
| Dextenza + Prednisolone Acetate | Ocular Therapeutix | Approved | 37 |